Providence Therapeutics Holdings Inc: PTX-COVID19-B

Providence Therapeutics Holdings Inc: PTX-COVID19-B

Vaccine Type: RNA

About Trial Phases

Phase 1: 1 Trial

PRO-CL-001, NCT04765436
Canada

Phase 2: 0 Trials

There are no trials for this phase.

Phase 3: 0 Trials

There are no trials for this phase.

Approvals: 0 Approvals

This vaccine is not yet approved.

Registered Trials

PRO-CL-001, NCT04765436
Phase 1
Canada
Total Enrollment: 60
Official Trial Registration:
- PRO-CL-001(Opens in new tab/window)
- NCT04765436(Opens in new tab/window)

© 2021 McGill COVID19 Vaccine Tracker Team

Funding provided by the McGill University Interdisciplinary Initiative in Infection and Immunity (MI4)

This site is provided for informational purposes only based on publically available data.

Site Credits Website Feedback Form